iShares Biotechnology ETF
859 hedge funds and large institutions have $5.31B invested in iShares Biotechnology ETF in 2023 Q1 according to their latest regulatory filings, with 78 funds opening new positions, 190 increasing their positions, 337 reducing their positions, and 95 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
859
Holders Change
-38
Holders Change %
-4.24%
% of All Funds
13.75%
Holding in Top 10
14
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-36.36%
% of All Funds
0.22%
New
78
Increased
190
Reduced
337
Closed
95
Calls
$300M
Puts
$354M
Net Calls
-$53.9M
Net Calls Change
+$132M
Top Buyers
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$197M |
| 2 |
JPMorgan Chase & Co
New York
|
+$156M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$139M |
| 4 |
Citigroup
New York
|
+$39.6M |
| 5 |
Two Sigma Advisers
New York
|
+$20.5M |
Top Sellers
| 1 |
CANY
Caxton Associates (New York)
New York
|
-$152M |
| 2 |
Jane Street
New York
|
-$98.3M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$72.5M |
| 4 |
E
Ergoteles
New York
|
-$59.5M |
| 5 |
JHU
Johns Hopkins University
Baltimore,
Maryland
|
-$52.6M |